Acadia Pharmaceuticals (ACAD) said late Tuesday it has struck a deal to sell its rare pediatric disease priority review voucher for $150 million.

Acadia said it was granted the voucher in March 2023 following approval from the US Food and Drug Administration of DAYBUE to treat Rett syndrome.

Acadia initially licensed DAYBUE from Neuren Pharmaceuticals in August 2018, and is required to pay Neuren a third of the net proceeds.

The company said it plans to invest the proceeds in commercial operations, research and development programs in the central nervous system and rare diseases, and in future business development.